Cargando…

SARS-CoV-2 Antibody Responses in Infection-Naive or Previously Infected Individuals After 1 and 2 Doses of the BNT162b2 Vaccine

This cohort study examines antibody responses in infection-naive and previously infected individuals after 1 and 2 doses of the BNT162b2 vaccine.

Detalles Bibliográficos
Autores principales:	Anderson, Mark, Stec, Michael, Rewane, Ayesan, Landay, Alan, Cloherty, Gavin, Moy, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346938/ https://www.ncbi.nlm.nih.gov/pubmed/34357399 http://dx.doi.org/10.1001/jamanetworkopen.2021.19741

Ejemplares similares

Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals
por: Kuzel, Timothy G, et al.
Publicado: (2023)

Correlation of Binding and Neutralizing Antibodies against SARS-CoV-2 Omicron Variant in Infection-Naïve and Convalescent BNT162b2 Recipients
por: Fu, Jia, et al.
Publicado: (2022)

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
por: Manisty, Charlotte, et al.
Publicado: (2021)

Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals
por: Muena, Nicolás A., et al.
Publicado: (2022)

SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals
por: Lombardi, Andrea, et al.
Publicado: (2021)

Negative effect of the second dose of the BNT162b2 vaccine in a significant percentage of individuals with previous COVID infection
por: Baos, Elvira, et al.
Publicado: (2022)

Detection of humoral and cellular immune response to anti-SARS-CoV-2 BNT162b2 vaccine in breastfeeding women and naïve and previously infected individuals
por: Cavic, Milena, et al.
Publicado: (2023)

Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations
por: Efrati, Shai, et al.
Publicado: (2021)

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
por: Ebinger, Joseph E., et al.
Publicado: (2021)

Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study
por: Shurrab, Farah M., et al.
Publicado: (2022)

Different decay of antibody response and VOC sensitivity in naïve and previously infected subjects at 15 weeks following vaccination with BNT162b2
por: Siracusano, Gabriel, et al.
Publicado: (2022)

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine
por: Prendecki, Maria, et al.
Publicado: (2021)

Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals
por: Ogrič, Manca, et al.
Publicado: (2022)

Contrasting specific antibody response to BNT162b2 mRNA vaccination in SARS-CoV-2-naive and previously infected nursing home residents
por: Chong, Yong, et al.
Publicado: (2022)

Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2
por: Speer, Claudius, et al.
Publicado: (2021)

T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study
por: Angyal, Adrienn, et al.
Publicado: (2022)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Robust Antibody Responses to the BNT162b2 mRNA Vaccine Occur Within a Week After the First Dose in Previously Infected Individuals and After the Second Dose in Uninfected Individuals
por: Hirotsu, Yosuke, et al.
Publicado: (2021)

BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
por: Choi, Seong-Ho, et al.
Publicado: (2023)

Spike Antibody Titers Evaluation after a 2-Dose Regimen of BNT162b2 Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2
por: Kayukawa, Satoshi, et al.
Publicado: (2021)

Breakthrough infections with SARS-CoV-2 omicron efficiently boost antibodies from previous BNT162b2 vaccinations
por: Perkmann, Thomas, et al.
Publicado: (2023)

The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects
por: Vicenti, Ilaria, et al.
Publicado: (2021)

Detection of SARS-CoV-2 antibodies after confirmed Omicron BA.1 and presumed BA.4/5 infections using Abbott ARCHITECT and Panbio assays
por: Boler, Michael, et al.
Publicado: (2023)

T‐cell response after first dose of BNT162b2 SARS‐CoV‐2 vaccine among healthcare workers with previous infection or cross‐reactive immunity
por: Casado, Jose L, et al.
Publicado: (2021)

Antibody response in individuals infected with SARS-CoV-2 early after the first dose of the BNT162b2 mRNA vaccine
por: Gobbi, Federico, et al.
Publicado: (2021)

Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection
por: Jones, Nick K, et al.
Publicado: (2021)

Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients: A multicenter prospective observational study
por: Haase, Michael, et al.
Publicado: (2022)

Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection
por: Urbanowicz, Richard A., et al.
Publicado: (2021)

Breakthrough Infections in BNT162b2-Vaccinated Health Care Workers
por: Lange, Bettina, et al.
Publicado: (2021)

Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents
por: Prunas, Ottavia, et al.
Publicado: (2022)

Temporal relation between second dose BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection
por: Ammirati, Enrico, et al.
Publicado: (2021)

High levels of anti–SARS-CoV-2 IgG antibodies in previously infected patients with cancer after a single dose of BNT 162b2 vaccine
por: Fong, Dominic, et al.
Publicado: (2021)

Immunogenicity of two doses of BNT162b2 and mRNA‐1273 vaccines for solid cancer patients on treatment with or without a previous SARS‐CoV‐2 infection
por: La Verde, Nicla, et al.
Publicado: (2022)

Evaluation of the immune response to COVID-19 vaccine mRNA BNT162b2 and correlation with previous COVID-19 infection
por: Bongiovanni, Marco, et al.
Publicado: (2021)

Previous COVID-19 infection, but not Long-COVID, is associated with increased adverse events following BNT162b2/Pfizer vaccination
por: Raw, Rachael Kathleen, et al.
Publicado: (2021)

POS-940 ANTIBODY RESPONSE TO PFIZER BNT162b2 VACCINE IN HEMODIALYSIS PATIENTS: THE PREVIOUS SARS-CoV-2 INFECTION INFLUENCE
por: FREITAS, M., et al.
Publicado: (2022)

Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2
por: Lustig, Yaniv, et al.
Publicado: (2021)

CoronaVac or BNT162b2 Vaccine as a Third Dose
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Safety and Immunogenicity of a Booster Vaccination by CoronaVac or BNT162b2 in Previously Two-Dose Inactivated Virus Vaccinated Individuals with Negative Neutralizing Antibody
por: Lai, Kristi Tsz-Wan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hmd08i2239viu81h8a0ppbq88m